Deutetrabenazine

Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Association Annual Meeting

Retrieved on: 
Monday, May 3, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Deutetrabenazine, Huntington's disease

AUSTEDO was administered using a response-driven dosing regimen, titrating up to a maximum total daily dose of 48 mg/day based on dyskinesia control and tolerability.

Key Points: 
  • AUSTEDO was administered using a response-driven dosing regimen, titrating up to a maximum total daily dose of 48 mg/day based on dyskinesia control and tolerability.
  • Since differences in incidence rates may be related to different durations of observation, exposure-adjusted incidence rates (EAIRs) were used to calculate AE frequencies.
  • 269 (79.8 percent) patients reported \xe2\x89\xa51 AE and AEs considered by the investigator to be treatment related were reported in 154 (45.7 percent) patients.
  • You are cautioned not to put undue reliance on these forward-looking statements.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210503005013/en/\n'

Teva to Present New Data at The MDS Virtual Congress 2020 and Psych Congress 2020 Virtual Experience Evaluating Long-Term Treatment with AUSTEDO® (deutetrabenazine) Tablets

Retrieved on: 
Monday, September 14, 2020
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Organ systems, Neurological disorders, Huntington's disease, Nervous system, Health, RTT, Syndromes, Tardive dyskinesia, Deutetrabenazine, Chorea, Movement disorders, Differential diagnoses of depression, AUSTEDO® (deutetrabenazine), Teva

All abstracts presented at MDS Virtual Congress 2020 will be published in the Movement Disorders journal e-supplement and displayed as an e-poster in the 2020 Virtual Poster.

Key Points: 
  • All abstracts presented at MDS Virtual Congress 2020 will be published in the Movement Disorders journal e-supplement and displayed as an e-poster in the 2020 Virtual Poster.
  • Abstracts at the Psych Congress 2020 Virtual Experience will be available online in the virtual exhibit hall.
  • AUSTEDO is indicated for the treatment of chorea associated with Huntingtons disease and for the treatment of tardive dyskinesia in adults.
  • AUSTEDO is contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression.

Teva to Present New Data on AUSTEDO® (deutetrabenazine) Tablets at the MDS Virtual Congress 2020 and Psych Congress 2020 Virtual Experience

Retrieved on: 
Tuesday, September 8, 2020
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Huntington's disease, Organ systems, Health, Neurological disorders, Articles, Deutetrabenazine, Syndromes, RTT, Tardive dyskinesia, Teva Pharmaceuticals, The Movement Disorder Society, Tetrabenazine

Teva Neuroscience, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new study data on AUSTEDO (deutetrabenazine) will be presented at the International Parkinson and Movement Disorder Society annual congress (MDS Virtual Congress 2020) and during the Psych Congress 2020 Virtual Experience.

Key Points: 
  • Teva Neuroscience, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new study data on AUSTEDO (deutetrabenazine) will be presented at the International Parkinson and Movement Disorder Society annual congress (MDS Virtual Congress 2020) and during the Psych Congress 2020 Virtual Experience.
  • All abstracts presented at MDS Virtual Congress 2020 will be published in the Movement Disorders journal e-supplement and displayed as an e-poster in the 2020 Virtual Poster Hall.
  • Abstracts at the Psych Congress 2020 Virtual Experience will be available in the virtual exhibit hall.
  • AUSTEDO is indicated for the treatment of chorea associated with Huntingtons disease and for the treatment of tardive dyskinesia in adults.

China Approves AUSTEDO® For Treating Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults

Retrieved on: 
Monday, May 18, 2020
Health, Pharmaceutical, Branches of biology, Organ systems, Nervous system, Neurological disorders, Amphetamine, Huntington's disease, Tardive dyskinesia, Neurotransmitter transporters, Deutetrabenazine, Teva Pharmaceutical Industries, Vesicular monoamine transporter, Movement disorders, Huntington's Disease, Tardive Dyskinesia, AUSTEDO® (deutetrabenazine), Teva

This is the second approval and expected launch in China of a Teva specialty medicine, following the recent launch of TREANDA.

Key Points: 
  • This is the second approval and expected launch in China of a Teva specialty medicine, following the recent launch of TREANDA.
  • The approval of AUSTEDO in China is an exciting milestone for Teva," said Gianfranco Nazzi, Executive Vice President, International Markets, at Teva.
  • Tardive dyskinesia is a movement disorder characterized by repetitive and uncontrollable movements of the tongue, lips, face, trunk and extremities.
  • AUSTEDO is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia in adults and for the treatment of chorea associated with Huntingtons disease.

New Data For Teva AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets Included in Neurology

Retrieved on: 
Friday, May 1, 2020
Biotechnology, Pharmaceutical, Health, Health, Life sciences, Fremanezumab, Teva Pharmaceutical Industries, Articles, Teva, Pharmaceutical industry, Deutetrabenazine, AJOVY® (fremanezumab-vfrm) injection, AUSTEDO® (deutetrabenazine), Teva

Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new data for AJOVY (fremanezumab-vfrm) injection and AUSTEDO (deutetrabenazine) tablets have appeared in an online supplement to Neurology.

Key Points: 
  • Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new data for AJOVY (fremanezumab-vfrm) injection and AUSTEDO (deutetrabenazine) tablets have appeared in an online supplement to Neurology.
  • The data includes 23 abstracts that highlight a diverse set of data evaluating the efficacy and safety of AJOVY and AUSTEDO.
  • AJOVY can be administered in office by a healthcare professional or at home by a patient or caregiver.
  • Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients.

Teva Announces Registration Trials of Deutetrabenazine in Pediatric Patients with Tourette Syndrome Did Not Meet the Primary Endpoint

Retrieved on: 
Wednesday, February 19, 2020
Mental health, Health, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Drugs, Branches of biology, RTT, Deutetrabenazine, Huntington's disease, Tourette syndrome, Selective serotonin reuptake inhibitors, Fluoxetine, Palifermin, ARTISTS 1, ARTISTS 2, Tourette Syndrome, AUSTEDO® (deutetrabenazine), Teva

The ARTISTS 2 study was a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to evaluate the safety, tolerability and efficacy of deutetrabenazine in 158 pediatric patients (6-16 years) with moderate to severe Tourette Syndrome.

Key Points: 
  • The ARTISTS 2 study was a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to evaluate the safety, tolerability and efficacy of deutetrabenazine in 158 pediatric patients (6-16 years) with moderate to severe Tourette Syndrome.
  • Patients received either deutetrabenazine (low dose or high dose) or placebo using a 1:1:1 randomization over eight weeks of dosing.
  • Symptoms of Tourette Syndrome typically occur first in early childhood, with peak severity around the age of 10 years.
  • AUSTEDO should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.

Teva to Present New Data on AUSTEDO® (deutetrabenazine) Tablets at Psych Congress 2019

Retrieved on: 
Wednesday, October 2, 2019
Biotechnology, Other Health, General Health, Health, Pharmaceutical, Mental health, Infectious diseases, Clinical trials, Huntington's disease, RTT, Chemical compounds, Drugs, Organic compounds, Depression, Ketones, Tetrabenazine, Deutetrabenazine, Tardive dyskinesia, Suicidal ideation, Differential diagnoses of depression, AUSTEDO® (deutetrabenazine), Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new AUSTEDO (deutetrabenazine) data will be presented at the 32nd annual Psych Congress, October 3-6, 2019 in San Diego, California.

Key Points: 
  • Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new AUSTEDO (deutetrabenazine) data will be presented at the 32nd annual Psych Congress, October 3-6, 2019 in San Diego, California.
  • AUSTEDO is indicated for the treatment of chorea associated with Huntingtons disease and for the treatment of tardive dyskinesia in adults.
  • Depression and Suicidality in Patients with Huntingtons Disease: AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntingtons disease.
  • Contraindications: AUSTEDO is contraindicated in patients with Huntingtons disease who are suicidal, or have untreated or inadequately treated depression.